CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Financial Officer sold 40,000 shares at $45.29 ($1,811,600)
- 4 Planned sale Chief Financial Officer sold 40,000 shares at an average $46.61 ($1,864,239)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Option exercise Chief Executive Officer acquired 4,000 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 1,191 shares at $20.98 ($24,987)
- 4 Option exercise 10% owner acquired 7,176 shares (option exercise)
- 4 Option exercise Director acquired 7,176 shares (option exercise)
Page 5 of 11 · 207 filings